Interview with Patrik De Haes, Chief Executive Officer, ThromboGenics
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Address: Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 (0) 16 75 13 10
Web: http://thrombogenics.com/
Thrombogenics NV is a Belgium-based biopharmaceutical company focused on the discovery and development of medicines for the treatment of eye disease, vascular disease and cancer. The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Belgium’s Flanders region is a hotbed of biotech excellence, with numerous examples of university spin-offs being translated into commercial-stage companies and many of those later acquired by Big Pharma. Wouter…
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the…
Benelux is a crucial cluster for Bristol Myers Squibb (BMS), which recently started construction of its first European CAR-T cell therapy production centre at the Leiden Bio Science Park. Sally…
Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far…
Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus…
Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some…
Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years,…
Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV,…
Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure,…
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
See our Cookie Privacy Policy Here
